Business Wire

CA-TULA-TECHNOLOGY-INC

28.6.2021 10:02:06 CEST | Business Wire | Press release

Share
Tula Reveals Technology to Reduce CO2 by 11% in Mild Hybrid Diesel Vehicles

Tula Technology, Inc. , a leader in propulsion efficiency, has released the findings of a recent simulation study to evaluate the efficacy of its newest technology. The study validated that Tula’s Dynamic Skip Fire (DSF) developed for mild hybrid diesel vehicles reduced CO2 emissions in a 2.3 liter 4-cylinder 48-volt light commercial vehicle in challenging real-world conditions. When Tula’s software strategies were implemented, an additional 11% of CO2 was eliminated compared to industry-leading hybrid powertrains. The CO2 reduction can be achieved at a cost of only €200 ($235 USD) per vehicle.

For manufacturers of light duty commercial vehicles, this technology offers a compelling and cost-effective solution to achieve challenging Euro 7 emission standards expected to go into effect by 2026 for all new vehicles in Europe.

“We created a synergistic technology by combining mild hybrid powertrain controls with our diesel Dynamic Skip Fire, which has proven to be very effective at reducing NOX (nitrogen oxides) and CO2 (carbon dioxide) emissions in heavy duty trucks,” said R. Scott Bailey , president and CEO of Tula Technologies. “We call it electrified diesel Dynamic Skip Fire, or edDSF, and it will help manufacturers of light commercial vehicles meet challenging NOX standards in a cost-effective manner. Equally significant, our product performs even better in tougher real-world conditions than under test cycles.”

FEV, an international engineering partner to the auto industry, joined forces with Tula to develop this study. Tula will present the results at the virtual Diesel Powertrains 3.0 Conference (https://fev-live.com/diesel/conference-program/ ) Wednesday, June 30, at 10:35 Paris (CEST) / 16:35 Beijing.

The findings show that electrified diesel Dynamic Skip Fire (edDSF) can significantly reduce CO2 output through the synergies created by pairing a hybrid system with DSF while also providing a means to achieve upcoming low-NOX targets aimed at decreasing the pollution created by internal combustion engines. Fuel savings are an additional benefit of edDSF compared to other emissions management technologies that typically require burning additional fuel to produce the heat required to decrease tailpipe emissions. The economics of edDSF are compelling—over a six-month period, an urban delivery vehicle equipped with edDSF will save enough in fuel expenses to recoup the costs associated with Tula’s technology.

Bailey concluded, “We are excited to present our findings at this global conference. With edDSF, we are offering a leading-edge solution to help meet the tight deadline the EU has set to reduce emissions, and for vehicle powertrain development, 2026 is just around the corner. edDSF is one of the many patented technologies in Tula’s portfolio that help improve the environment by increasing the efficiency of engines and motors while reducing harmful emissions. I am very proud of our outstanding engineering team for continuing to develop new applications for our state-of-the art control technologies.”

About Tula Technology, Inc.

Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 340 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye